Skip to main content
Thomas Wisniewski, MD, Neurology, New York, NY

ThomasWisniewskiMD

Neurology • New York, NY

Neurodegenerative, Dementia & Geriatrics

Lulu P. and David J. Levidow Professor of Neurology, Department of Neurology Professor, Department of Pathology Professor, Department of Psychiatry Director, Alzheimer's Disease Center Director, Pearl I. Barlow Center for Memory Evaluation and TreatmentAssoc Chair for Research, Department of Neurology NYU Neurology Associates NYU Pearl Barlow Center for Memory Evaluation and Treatment

Join to view full profile

Dr. Wisniewski is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

  • Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
  • Connect with colleagues in the same hospital or clinic.
  • Read the latest clinical news, personalized to your specialty.

See Dr. Wisniewski's full profile

Already have an account?

  • Office

    140 East 32nd Street
    New York, NY 10016
    Phone+1 212-263-2152
    Fax+1 212-263-3273

Summary

  • Dr. Wisniewski is a Neurologist and Neuropathologist, who is the Director of the NYU NIH funded Alzheimer’s Disease Research Center (ADRC). He also directs the Conformational Disorders Laboratory, the Center of Cognitive Neurology, the NYS NYU Center for Excellence for Alzheimer’s Disease (CEAD), the Pearl Barlow Memory Disorders Center, the Division of Aging and Dementia and the Neuropathology Fellowship program. He is also on the Board of the NYC Chapter of the Alzheimer’s Association. He has been a member of the NYULH faculty council since 2012 and a member of the NYU Senate since 2013. His Laboratory has been working on elucidating the pathogenesis of Alzheimer's disease (AD) and prion diseases, with an aim to develop possible therapeutic strategies. This work has led to >300 peer reviewed publications (h-index ~80), 25 issued US patents and has been continuously funded by NIH for >26yrs. His lab has helped develop novel therapeutic methods for AD in particular various immunotherapeutic approaches that affect both the adaptive and innate immune systems. His group was the first to document the effectiveness of vaccination in prion disease in vivo using wild type mice and were also the first group to effectively use mucosal immunization to partially prevent a prion infection (chronic wasting disease) in white tailed deer, which are naturally at risk for this prion infection. His lab has also developed both active and passive immunization specifically targeting abnormal oligomeric protein conformation, as well as a means to stimulate innate immunity to ameliorate AD pathology. Recently, his group developed an unbiased localized proteomic methodology that produces robust data utilizing archival formalin, fixed paraffin embedded human tissue and used this method perform the most extensive proteomic analysis of amyloid plaques, as well as to characterize the amyloid proteome of a distinct subtype of AD: rapidly progressive AD.

Education & Training

  • New York Presbyterian Hospital (Columbia Campus)
    New York Presbyterian Hospital (Columbia Campus)Fellowship, Neuropathology, 1989 - 1990
  • New York Presbyterian Hospital (Columbia Campus)
    New York Presbyterian Hospital (Columbia Campus)Residency, Pathology-Anatomic and Clinical, 1988 - 1989
  • NYU Grossman School of Medicine
    NYU Grossman School of MedicineResidency, Neurology, 1985 - 1988
  • SUNY Downstate Health Sciences University
    SUNY Downstate Health Sciences UniversityInternship, Transitional Year, 1984 - 1985
  • (King's College London - School of Medicine)
    (King's College London - School of Medicine)Class of 1982
  • University of London, King's College
    University of London, King's CollegeBS, 1980

Certifications & Licensure

  • NY State Medical License
    NY State Medical License 1987 - 2026
  • American Board of Pathology Neuropathology
  • American Board of Psychiatry and Neurology Neurology

Awards, Honors, & Recognition

  • ANA Award for Clinical and Scientific Excellence – Career Based Contributions over 15 years American Neurological Association, 2023
  • Casimir Funk Award in the Natural Sciences Polish Institute of Arts and Sciences of America, 2023
  • Elected as Distinguished Fellow Kosciuszko Foundation Collegium of Eminent Scientists, 2014
  • Join now to see all

Publications & Presentations

PubMed

Journal Articles

  • Blocking the Apolipoprotein E/Amyloid Beta Interaction in Triple Transgenic Mice Ameliorates Alzheimer's Disease Related Amyloid Betaeta and Tau Pathology  
    Liu S, Breitbart A, Sun Y, Mehta PD, Boutajangout A, Scholtzova H, Wisniewski T, Journal of Neurochemistry, 1/1/2014
  • Two Phase 3 Trials of Bapineuzumab in Mild to Moderate Alzheimer's Disease  
    Salloway S, Sperling R, Fox NC, Blennow K, Klunk W, Raskind M, Sabbagh M, Honig LS, Porsteinsson AP, Ferris S, Reichert M, Ketter N, Nejadnik B, Guenzler V, Miloskavsk..., New England Journal of Medicine, 1/1/2014
  • Nerve Growth Factor Metabolic Dysfunction in Down's Syndrome Brains: a Cause for Cholinergic Degeneration?  
    Iulita MF, Carmo SD, Ower A, Fortress A, Aguilar LF, Hanna M, Wisniewski T, Granholm AC, Buhusi M, Busciglio J, Cuello AC, Brain, 1/1/2014
  • Join now to see all

Books/Book Chapters

  • The Neuroscience of Autism Spectrum Disorders 
    Chapter: Clinicopathological Stratification of Idiopathic Autism Associated with Duplications 15q11.2-q13 
    Page 347 - 359Wegiel J, Schanen NC, Cook EH, Brown WT, Kuchna I, Nowicki K, Wegiel J, Imaki H, Ma SY, London E, Wisniewski TEditors: Joseph D. Buxbaum & Patrick R..Elsevier, Amsterdam2012
  • Prions and Diseases 
    Chapter: Immunomodulation 
    Page 267 - 287Wisniewski, T, Goni, FEditors: Zou, W. Q., Gambetti, P..Springer, New York2012
  • Neuroimaging of Cognitive Disorders: Commentary 
    Chapter: Chapter 28 in Understanding Neuropsychiatric Disorders 
    Page 395 - 401de Leon MJ, Rusinek H, Tsui W, Wisniewski T, Wegiel J, George AEditors: Shenton ME, Turetsky BI.Cambridge University Press2010
  • Join now to see all

Other

Press Mentions

  • What Is the Brain Fog That Affects Covid-19 Patients?
    What Is the Brain Fog That Affects Covid-19 Patients?July 23rd, 2022
  • Is Long COVID a Syndrome or a Series of Coronavirus Complications? What We Know Now About Lingering Symptoms
    Is Long COVID a Syndrome or a Series of Coronavirus Complications? What We Know Now About Lingering SymptomsJanuary 25th, 2022
  • Biomarkers of Neurodegeneration Elevated in Hospitalized Covid-19 Patients
    Biomarkers of Neurodegeneration Elevated in Hospitalized Covid-19 PatientsJanuary 18th, 2022
  • Join now to see all

Professional Memberships

Dr. Thomas Wisniewski, Dr. Thomas Wisniewski, MD, Dr. T Wisniewski